Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 19/20 | 0.70 |
| ▸ | PPARD | Q03181 | 4/20 | 0.63 |
| ▸ | PPARA | Q07869 | 3/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5204909 | 0.98 | PPARG (0.70) | PPARGPPARDPPARA | |
| SCHEMBL5759203 | 0.95 | PPARG (0.71) | PPARGPPARDPPARA | |
| SCHEMBL5204103 | 0.94 | PPARG (0.65) | PPARGPPARDPPARA | |
| SCHEMBL5208705 | 0.93 | PPARG (0.69) | PPARGPPARDPPARA | |
| SCHEMBL5205079 | 0.92 | PPARG (0.62) | PPARGPPARDPPARA | |
| SCHEMBL5208262 | 0.91 | PPARG (0.67) | PPARGPPARDPPARA | |
| SCHEMBL5205755 | 0.90 | PPARG (0.57) | PPARGPPARDPPARA | |
| SCHEMBL5208868 | 0.90 | PPARG (0.59) | PPARGPPARDPPARA | |
| SCHEMBL5204189 | 0.89 | PPARG (0.60) | PPARGPPARDPPARA | |
| SCHEMBL5211160 | 0.89 | PPARG (0.60) | PPARGPPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007127791-A2 | NEW PHARMACOLOGICAL METHOD FOR TREATMENT OF NEUROPATHIC PAIN | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2007-11-08 | — | — | WO | claimed |
| US-20070249561-A1 | Pharmacological method for treatment of neuropathic pain | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND | 2007-10-25 | — | — | US | claimed |
| WO-2000078314-A1 | PROCESS FOR MAKING ARYLTHIAZOLIDINEDIONE DERIVATIVES | MERCK & CO., INC. (US) | 2000-12-28 | — | — | WO | claimed |
| WO-2007127791-A2 | NEW PHARMACOLOGICAL METHOD FOR TREATMENT OF NEUROPATHIC PAIN | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) | 2007-11-08 | — | — | WO | disclosed |
| US-20070249561-A1 | Pharmacological method for treatment of neuropathic pain | THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND | 2007-10-25 | — | — | US | disclosed |
| EP-1040102-B1 | ARYLTHIAZOLIDINEDIONE DERIVATIVES | MERCK & CO INC (US) | 2007-01-24 | — | — | EP | disclosed |
| EP-1194146-B1 | ARYLTHIAZOLIDINEDIONE AND ARYLOXAZOLIDINEDIONE DERIVATIVES | MERCK & CO INC (US) | 2006-07-19 | — | — | EP | disclosed |
| EP-1040102-A4 | ARYLTHIAZOLIDINEDIONE DERIVATIVES | MERCK & CO INC (US) | 2002-11-27 | — | — | EP | disclosed |
| EP-1194146-A4 | ARYLTHIAZOLIDINEDIONE AND ARYLOXAZOLIDINEDIONE DERIVATIVES | MERCK & CO INC (US) | 2002-07-31 | — | — | EP | disclosed |
| US-6399640-B1 | ANTIDIABETIC AGENTS; ANTICHOLESTEROL AGENTS | MERCK & CO., INC. | 2002-06-04 | — | — | US | disclosed |
| EP-1194146-A1 | ARYLTHIAZOLIDINEDIONE AND ARYLOXAZOLIDINEDIONE DERIVATIVES | Merck & Co., Inc. (US) | 2002-04-10 | — | — | EP | disclosed |
| WO-2000078314-A8 | PROCESS FOR MAKING ARYLTHIAZOLIDINEDIONE DERIVATIVES | MERCK & CO INC (US) | 2001-12-06 | — | — | WO | disclosed |
| US-6200998-B1 | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONISTS; ANTICHOLESTEROL, ANTIDIABETIC AND ANTIOBESITY AGENTS | MERCK & CO., INC. | 2001-03-13 | — | — | US | disclosed |
| WO-2000078314-A1 | PROCESS FOR MAKING ARYLTHIAZOLIDINEDIONE DERIVATIVES | MERCK & CO., INC. (US) | 2000-12-28 | — | — | WO | disclosed |
| WO-2000078312-A1 | ARYLTHIAZOLIDINEDIONE AND ARYLOXAZOLIDINEDIONE DERIVATIVES | MERCK & CO., INC. (US) | 2000-12-28 | — | — | WO | disclosed |
| WO-2000078314-A1 | PROCESS FOR MAKING ARYLTHIAZOLIDINEDIONE DERIVATIVES | MERCK & CO., INC. (US) | 2000-12-28 | — | — | WO | disclosed |
| EP-1040102-A1 | ARYLTHIAZOLIDINEDIONE DERIVATIVES | Merck & Co., Inc. (US) | 2000-10-04 | — | — | EP | disclosed |
| US-6008237-A | POTENT AGONISTS OF PEROXIDSOME PROLIFERATOR ACTIVATED RECEPTOR; FOR CONTROLLING OR PREVENTING OF DIABETES, HYPERGLYCEMIA, HYPERLIPIDEMIA, HYPERCHOLESTEROLEMIA, ATHEROSCLEROSIS, OBESITY, VASCULAR RESTENOSIS | MERCK & CO., INC. (US) | 1999-12-28 | — | — | US | disclosed |
| WO-1999032465-A1 | ARYLTHIAZOLIDINEDIONE DERIVATIVES | MERCK & CO., INC. (US) | 1999-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249561-A1 | Pharmacological method for treatment of neuropathic pain | PPARG, PPARA, CNR2 | PPARG 1/4885PPARD 8/4885PPARA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.